Unmarried people given less intensive treatment for mantle c
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Mantle cell lymphoma is a malignant disease in which intensive treatment can prolong life. In a new study, scientists show that people with mantle cell lymphoma who were unmarried, and those who had low educational attainment, were less often treated with stem-cell transplantation, which may result in poorer survival. The findings have been published in the scientific journal Blood Advances.

Patients diagnosed with mantle cell lymphoma (MCL) where the disease has spread receive intensive treatment with cytotoxic drugs and stem-cell transplantation. In a new study, researchers looked at which people are more likely to be offered transplants, and compared survival between those selected for transplantation versus those not selected. The study showed that transplantation prolongs life, but that people who were unmarried or had a lower level of education received a transplant less often.

The study included 369 patients from all over Sweden, diagnosed with MCL. Among them, 40 percent did not undergo a transplant during the initial treatment. According to the researchers, this was a surprisingly high proportion.

Mortality within 100 days after transplantation was low, which also indicates that it is a safe treatment that could probably have been considered more often in Sweden. For people who are still unable to undergo a transplant, the study suggests that, instead of cytotoxic drugs alone, the option of providing new, modern, and targeted drugs should be considered.

"Studies of this kind are important because they can lead to certain groups in society being offered more support. They can also act as an eye-opener for patients, health professionals, and politicians alike, showing that there's still a need for more equality in health care in Sweden," says the author.

Source: https://doi.org/10.1182/bloodadvances.2020003645